SAN DIEGO, Dec. 16 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (Amex: MII)
announced today an expanded research collaboration with the University of
Alberta, Edmonton in the area of human islet cell transplantation therapies
for treatment of insulin-dependent diabetes.
Under the terms of the agreement, MicroIslet and University of Alberta
scientists will conduct animal studies utilizing MicroIslet's proprietary
technologies for encapsulating islet cells that have been isolated from human
cadavers. MicroIslet's management believes the successful completion of these
joint studies is a prerequisite for future clinical pilot studies of its
encapsulation technology in humans.
MicroIslet and University of Alberta scientists are hopeful that the work
will be another important step in minimizing the need for immunosuppression in
patients who undergo the transplantation of insulin-producing islet cells
under the Edmonton Protocol.
The work in Edmonton will be conducted by a group led by Dr. James Shapiro
and Dr. Jonathan Lakey, pioneering scientists in the field of human islet
transplantation and key leaders of the team that developed the Edmonton
As part of this collaboration, MicroIslet will provide financial support
and technical assistance to the Edmonton team. The University of Alberta will
contribute significant resources, including the transplantation expertise of
its scientists and access to its facilities.
This project will be conducted in parallel with MicroIslet's ongoing
studies using encapsulated pig islet cells (xenotransplantation) at The
Scripps Research Institute in La Jolla, California, and the California
Regional Primate Center at the University of California, Davis.
MicroIslet is a biotechnology company engaged in the research,
development, and commercialization of patented technologies in the field of
transplantation therapy for people with insulin-dependent diabetes.
MicroIslet's patented islet transplantation technology, exclusively licensed
from Duke University, includes methods for isolating, culturing,
cryopreservation, and immuno-protection (microencapsulation) of islet cells.
MicroIslet is working to develop and commercialize a first product, called
MicroIslet-P, a microencapsulated porcine islet cell suspension that will be
used for transplantation in patients with insulin-dependent diabetes.
Additional information about MicroIslet can be found at www.microislet.com.
Except for the historical information contained herein, the matters set
forth in this press release, including the expectation of development of new
therapeutic products, and the impact of MicroIslet's products on diabetes
patients, are forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to risks and uncertainties that
may cause actual results to differ materially, including the risks and
uncertainties inherent in medical treatment discovery, development and
commercialization, the risks and uncertainties associated with MicroIslet's
early stage xenotransplantation technologies, the risks and uncertainties of
governmental approvals and regulation, MicroIslet's need to raise substantial
additional capital to proceed through human clinical trials and bring any
product to market, the risks that MicroIslet's competitors will develop or
market technologies or products that are more effective or commercially
attractive than MicroIslet's products, and other risks detailed from time to
time in MicroIslet's most recent filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the date
hereof. MicroIslet disclaims any intent or obligation to update these
For more information, please visit our Web site at www.microislet.com.
For further information, contact:
Haro Hartounian, Ph.D.
President and Chief Operating Officer, MicroIslet Inc.
Jonathan Lakey, Ph.D.
Professor of Surgery, University of Alberta, Edmonton
+1-780-492-3077, email@example.com, www.ualberta.ca
SOURCE MicroIslet Inc.
/CONTACT: Haro Hartounian, Ph.D., President and Chief Operating Officer,
MicroIslet Inc., +1-858-657-0287, firstname.lastname@example.org; or Jonathan Lakey,
Ph.D., Professor of Surgery, University of Alberta, Edmonton, +1-780-492-3077,
/Web site: http://www.ualberta.ca /
/Web site: http://www.microislet.com /
CO: MicroIslet Inc.; University of Alberta, Edmonton
ST: California, Alberta
IN: HEA MTC BIO HED
SU: JVN SVY
-- LATH019 --
8696 12/16/2004 08:00 EST http://www.prnewswire.com